FMP
NASDAQ
11.31 USD
0.11 (0.973%)
Mr. Rohan Palekar
Healthcare
Biotechnology
https://www.89bio.com
NASDAQ
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
0001785173
US2825591033
282559103
142 Sansome Street
415 432 9270
US
70
Nov 11, 2019
0001785173
NASDAQ
Biotechnology
Healthcare
282559103
US2825591033
US
11.31
0.95
1.37M
1.06B
-
6.575-22.93
4.06
-
-
-
-
-5.65
-
https://www.89bio.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.